- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05923073
Een studie van Guselkumab bij pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn (MACARONI-23)
Een fase 3, multicenter, gerandomiseerd, platformonderzoek van p19-remming van de IL-23-route om werkzaamheid vast te stellen bij de ziekte van Crohn bij kinderen
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
-
Nedlands, Australië, 6009
- Werving
- Perth Children's Hospital
-
South Brisbane, Australië, 4101
- Werving
- Mater Hospital Brisbane
-
Westmead, Australië, 2145
- Werving
- The Children's Hospital at Westmead
-
-
-
-
-
Brussels, België, 1090
- Werving
- Universitair Ziekenhuis Brussel
-
Brussels, België, 1200
- Werving
- Cliniques Universitaires Saint Luc
-
Ghent, België, 9000
- Werving
- Universitair Ziekenhuis Gent
-
Leuven, België, 3000
- Werving
- UZ Leuven
-
-
-
-
-
Campinas, Brazilië, 13060-904
- Werving
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, Brazilië, 80250-060
- Werving
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, Brazilië, 74605-020
- Werving
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, Brazilië, 90035-074
- Werving
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brazilië, 90035-007
- Werving
- Hospital De Clinicas De Porto Alegre
-
Vitória, Brazilië, 29040-091
- Werving
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, Brazilië, 100000
- Werving
- INTEGRAL Pesquisa e Ensino
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Werving
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Werving
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, Canada, M5G 1X8
- Werving
- Hospital For Sick Children
-
-
-
-
-
Amiens, Frankrijk, 80054
- Werving
- CHU Amiens-Hopital Nord
-
Lille, Frankrijk, 59037
- Werving
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, Frankrijk, 75019
- Werving
- Hôpital Robert Debré
-
Paris, Frankrijk, 75015
- Werving
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Beersheba, Israël, 84101
- Werving
- Soroka University Medical Center
-
Be’er Ya‘aqov, Israël, 70300
- Werving
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, Israël, 9103102
- Werving
- Shaare Zedek Medical Center
-
Jerusalem, Israël, 9124001
- Werving
- Hadassah Medical Center
-
Petah Tikva, Israël, 4920235
- Werving
- Schneider Children's Medical Center
-
Rehovot, Israël, 761001
- Werving
- Kaplan Medical Center
-
-
-
-
-
Alessandria, Italië, 15121
- Werving
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, Italië, 24127
- Werving
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Italië, 40124
- Werving
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, Italië, 50139
- Werving
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, Italië, 20154
- Werving
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, Italië, 161
- Werving
- AOU Policlinico Umberto I
-
-
-
-
-
Hirosaki, Japan, 036-8563
- Werving
- Hirosaki University Hospital
-
Kagoshima, Japan, 890-8544
- Werving
- Kagoshima University Hospital
-
Kashiwa-shi, Japan, 277-0871
- Werving
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Japan, 650 0017
- Werving
- Kobe University Hospital
-
Saga, Japan, 849-8501
- Werving
- Saga University Hospital
-
Sendai, Japan, 989-3126
- Werving
- Miyagi Childrens Hospital
-
Setagaya Ku, Japan, 157 8535
- Werving
- National Center for Child Health and Development
-
Tokyo, Japan, 113-8431
- Werving
- Juntendo University Hospital
-
Tsu, Japan, 514 8507
- Werving
- Mie University Hospital
-
Ube, Japan, 755-8505
- Werving
- Yamaguchi University Hospital
-
Yokohama, Japan, 232-0024
- Werving
- Yokohama City University Medical Center
-
Yokohama, Japan, 230-8765
- Werving
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Rotterdam, Nederland, 3015 GD
- Werving
- Erasmus Medisch Centrum
-
-
-
-
-
Nordbyhagen, Noorwegen, 1474
- Werving
- Akershus Universitetssykehus HF
-
Oslo, Noorwegen, 424
- Werving
- Oslo University Hospital
-
Tromsø, Noorwegen, 9038
- Werving
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Noorwegen, 7030
- Werving
- St. Olavs Hospital
-
-
-
-
-
Vienna, Oostenrijk, 1090
- Werving
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Rzeszów, Polen, 35-302
- Werving
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polen, 04 501
- Werving
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polen, 04 730
- Werving
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Braga, Portugal, 4710-243
- Werving
- Hospital de Braga
-
Lisbon, Portugal, 1649-035
- Werving
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, Portugal, 4200-319
- Werving
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Córdoba, Spanje, 14004
- Werving
- Hosp Reina Sofia
-
Sabadell, Spanje, 8208
- Werving
- Corporacio Sanitari Parc Tauli
-
Valencia, Spanje, 46026
- Werving
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Glasgow, Verenigd Koninkrijk, G51 4TF
- Werving
- Royal Hospital for Sick Children
-
London, Verenigd Koninkrijk, WC1N 3JH
- Werving
- Great Ormond Street Hospital
-
Manchester, Verenigd Koninkrijk, M13 9WL
- Werving
- Royal Manchester Children's Hospital
-
Manchester, Verenigd Koninkrijk, M13 9WL
- Werving
- Nowgen Centre, Research and Innovation
-
Oxford, Verenigd Koninkrijk, OX3 9DU
- Werving
- John Radcliffe Hospital
-
Sheffield, Verenigd Koninkrijk, S10 2TH
- Werving
- Sheffield Children's Hospital
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90048
- Werving
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Werving
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University
-
Atlanta, Georgia, Verenigde Staten, 30342
- Werving
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202-5225
- Werving
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Werving
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Werving
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Verenigde Staten, 10032
- Werving
- Columbia University Medical Center
-
New York, New York, Verenigde Staten, 10021-5663
- Werving
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, Verenigde Staten, 45404
- Werving
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, Verenigde Staten, 05446
- Werving
- University of Vermont Medical Center
-
-
-
-
-
Busan, Zuid -Korea, 48108
- Werving
- Inje University Haeundae Paik Hospital
-
Daegu, Zuid -Korea, 41404
- Werving
- Kyungpook National University Chilgok Hospital
-
Seoul, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital
-
Seoul, Zuid -Korea, 06351
- Werving
- Samsung Medical Center
-
Seoul, Zuid -Korea, 120-752
- Werving
- Severance Hospital Yonsei University Health System
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Andere namen:
Guselkumab will be administered intravenously.
Andere namen:
|
|
Experimenteel: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Andere namen:
Guselkumab will be administered intravenously.
Andere namen:
|
|
Experimenteel: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andere namen:
Guselkumab will be administered intravenously.
Andere namen:
|
|
Experimenteel: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andere namen:
Guselkumab will be administered intravenously.
Andere namen:
|
|
Experimenteel: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Andere namen:
Guselkumab will be administered intravenously.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
Tijdsspanne: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Tijdsspanne: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
Tijdsspanne: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
Tijdsspanne: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
Tijdsspanne: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
Tijdsspanne: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
Tijdsspanne: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Tijdsspanne: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Tijdsspanne: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
Tijdsspanne: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Tijdsspanne: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Tijdsspanne: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
Tijdsspanne: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
Tijdsspanne: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Clinical Trial, Janssen Research & Development, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CR109212
- 2021-006282-37 (EudraCT-nummer)
- CNTO1959PBCRD3007 (Andere identificatie: Janssen Research & Development, LLC)
- 2023-504735-41-00 (Register-ID: EUCT number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .